Eledon Pharmaceuticals Valuation
| ELDN Stock | USD 4.66 0.40 9.39% |
At this time, the firm appears to be undervalued. Eledon Pharmaceuticals shows a prevailing Real Value of $7.53 per share. The current price of the firm is $4.66. Our model computes the value of Eledon Pharmaceuticals from reviewing the firm fundamentals such as Shares Owned By Insiders of 0.04 %, shares owned by institutions of 42.88 %, and Current Valuation of 176.8 M as well as analyzing its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Eledon Pharmaceuticals' valuation include:
Price Book 3.346 | Enterprise Value 176.8 M | Enterprise Value Ebitda 0.8366 | Forward PE 5.3908 | Trailing PE 5.8356 |
Undervalued
Today
Please note that Eledon Pharmaceuticals' price fluctuation is slightly risky at this time. Calculation of the real value of Eledon Pharmaceuticals is based on 3 months time horizon. Increasing Eledon Pharmaceuticals' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Eledon Pharmaceuticals is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Eledon Stock. However, Eledon Pharmaceuticals' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 4.66 | Real 7.53 | Target 16.5 | Hype 4.82 | Naive 4.65 |
The intrinsic value of Eledon Pharmaceuticals' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Eledon Pharmaceuticals' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Eledon Pharmaceuticals helps investors to forecast how Eledon stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Eledon Pharmaceuticals more accurately as focusing exclusively on Eledon Pharmaceuticals' fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Eledon Pharmaceuticals' intrinsic value based on its ongoing forecasts of Eledon Pharmaceuticals' financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Eledon Pharmaceuticals' closest peers.
Eledon Pharmaceuticals Cash |
|
Eledon Valuation Trend
Knowing Eledon Pharmaceuticals' actual value is paramount for traders when making sound investment determinations. Using both Eledon Pharmaceuticals' enterprise value as well as its market capitalization is the best way to estimate the value of the company and is usually enough for investors to make market timing decisions.
Eledon Pharmaceuticals Total Value Analysis
Eledon Pharmaceuticals is currently forecasted to have valuation of 176.8 M with market capitalization of 254.49 M, debt of 383 K, and cash on hands of 70.46 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Eledon Pharmaceuticals fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
176.8 M | 254.49 M | 383 K | 70.46 M |
Eledon Pharmaceuticals Asset Utilization
One of the ways to look at asset utilization of Eledon is to check how much profit was generated for every dollar of assets it reports. Eledon Pharmaceuticals shows a negative utilization of assets of -0.33 percent, losing $0.003336 for each dollar of assets held by the firm. Inadequate asset utilization denotes the company is being less effective with each dollar of assets it shows. Put another way, asset utilization of Eledon Pharmaceuticals shows how discouraging it operates for each dollar spent on its assets.Eledon Pharmaceuticals Ownership Allocation
Eledon Pharmaceuticals holds a total of 59.74 Million outstanding shares. 30% of Eledon Pharmaceuticals outstanding shares are owned by other corporate entities. Institutional investors are typically referred to investors that purchase positions in a given stock to benefit from reduced commissions. Consequently, institutional investors are subject to different rules and regulations than regular investors. Please look out for any change in current institutional holding as this could mean something significant has changed at the company or is about to change. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.Eledon Pharmaceuticals Profitability Analysis
Net Loss for the year was (40.33 M) with profit before overhead, payroll, taxes, and interest of 0.About Eledon Pharmaceuticals Valuation
We use absolute and relative valuation methodologies to arrive at the intrinsic value of Eledon Pharmaceuticals. In general, an absolute valuation paradigm, as applied to this company, attempts to find the value of Eledon Pharmaceuticals based exclusively on its fundamental and basic technical indicators. By analyzing Eledon Pharmaceuticals's financials, quarterly and monthly indicators, and their related drivers, we attempt to find the most accurate representation of Eledon Pharmaceuticals's intrinsic value. As compared to an absolute model, our relative valuation model uses a comparative analysis of Eledon Pharmaceuticals. We calculate exposure to Eledon Pharmaceuticals's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Eledon Pharmaceuticals's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | -374 K | -355.3 K | |
| Pretax Profit Margin | (174.11) | (182.82) | |
| Operating Profit Margin | (138.49) | (145.41) | |
| Net Loss | (171.08) | (179.64) | |
| Gross Profit Margin | (0.47) | (0.50) |
Eledon Pharmaceuticals Growth Indicators
Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines.
| Common Stock Shares Outstanding | 24.6 M | |
| Forward Price Earnings | 5.3908 |
Eledon Pharmaceuticals Current Valuation Indicators
Eledon Pharmaceuticals' valuation analysis is a process of estimating the intrinsic value of all assets and outstanding equities. There are different methodologies and models we use to develop the final Eledon Pharmaceuticals' valuation. The techniques such as discounted cash flow and fundamental indicators such as book value per share or market capitalization are well known and widely used across most financial advisers and money managers.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Eledon Pharmaceuticals, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Eledon Pharmaceuticals' valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Eledon Pharmaceuticals' worth.When determining whether Eledon Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Eledon Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Eledon Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Eledon Pharmaceuticals Stock: Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Eledon Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment. To learn how to invest in Eledon Stock, please use our How to Invest in Eledon Pharmaceuticals guide.You can also try the Portfolio File Import module to quickly import all of your third-party portfolios from your local drive in csv format.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Eledon Pharmaceuticals. If investors know Eledon will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Eledon Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share 0.73 | Return On Assets (0.33) | Return On Equity (0.25) |
The market value of Eledon Pharmaceuticals is measured differently than its book value, which is the value of Eledon that is recorded on the company's balance sheet. Investors also form their own opinion of Eledon Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Eledon Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Eledon Pharmaceuticals' market value can be influenced by many factors that don't directly affect Eledon Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Eledon Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Eledon Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Eledon Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.